Libida vs Bremelanotide Nasal Spray: What’s in Each, What Each Costs, and Why Neither Is a Proven Winner

The HRT Index Editorial TeamIndependent women's health research

Published:August 11, 2026Last reviewed:August 11, 2026

Editorial research — not medically reviewed by a clinician. Why this label

Last updated: August 11, 2026 · Last verified: August 11, 2026 · By The HRT Index Editorial Team. Educational research, not medical advice, and not reviewed by a clinician. See our medical review policy. Full disclosure.

Before choosing a needle-free route

The right starting point depends on your symptoms, age, risk history, medication route, insurance, and state. Organize those questions before paying for a compounded product.

Find My HRT Path

Libida vs bremelanotide nasal spray has no proven winner, and neither finished product is FDA-approved. Libida fits women who prefer a countable sublingual tablet with added oxytocin; a spray fits women who prefer nasal dosing without oxytocin. Libida starts at $199 monthly or $249 once; Wisp starts at $175. Neither fits anyone needing FDA-reviewed evidence.

Here’s the part almost nobody mentions. Palatin Technologies developed bremelanotide as a nasal product first — and stopped pursuing that route for sexual dysfunction after reporting blood-pressure increases in some patients and significant variation in plasma levels. That history does not prove today’s compounded sprays are unsafe. It does tell you why “needle-free” is not the only fact that matters.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

Looking for general information rather than these two products? Start with our guide to low libido in menopause.

Why are you comparing the two needle-free options?

You have probably already decided that injecting a medication before intimacy is not the experience you want. That is a legitimate preference. This page does not try to sell you back into the needle; it compares the two compounded, needle-free routes on the facts their sellers publish — and on the facts they leave out.

Both products exist because the FDA-approved bremelanotide product, Vyleesi, is a subcutaneous autoinjector used before anticipated sexual activity. A woman can understand that Vyleesi has the strongest evidence and still decide she does not want an injection.

That decision is reasonable. It also creates the exact trade you need to see clearly: a needle-free route may feel easier, but neither finished needle-free product has FDA-reviewed dosing, pharmacokinetic, efficacy, or safety data.

So we are going to skip the question you already answered and answer yours.

Best for / not for you

A nasal bremelanotide product may fit your route preference if:

You want a needle-free, on-demand spray and do not want oxytocin added.
You can get the concentration, milligrams per spray, bottle yield, maximum frequency, full charge, and renewal terms in writing before paying.
Nasal congestion, year-round rhinitis, frequent colds, or spray technique are not likely to make the route frustrating for you.
The prescriber reviews your blood pressure, cardiovascular history, pregnancy status, and complete medication list rather than relying on a product-page quiz alone.

Libida may fit your route preference if:

You would rather use a countable sublingual tablet than a spray bottle.
You specifically want a formula that includes oxytocin and understand that clinical evidence does not establish the oxytocin addition as an advantage.
You want a publicly disclosed tablet strength: Inner Balance lists 1 mg bremelanotide plus 20 IU oxytocin per tablet in its help center.
You understand the difference between the advertised monthly equivalent and the amount charged to your card.
You can accept that Inner Balance’s public refund policy expressly excludes Libida from its money-back guarantee.

Neither should be your next click if:

You have uncontrolled high blood pressure or known cardiovascular disease. Those are contraindications on the FDA-approved bremelanotide label, and the compounded products do not have route-specific FDA labels that replace that safety benchmark.
You are pregnant, trying to conceive, or breastfeeding without direct clinician guidance.
Your low desire started with a new medication, painful sex, depression, severe sleep disruption, a thyroid problem, relationship distress, or another issue that needs its own assessment.
You need an FDA-reviewed product, a measured systemic exposure, a product-specific trial, or predictable insurance coverage before you are comfortable spending money.
You are postmenopausal and have not discussed the FDA-approved medication now available to women under 65 who meet the criteria for acquired, generalized HSDD.

We would genuinely rather lose your click than watch you spend $175 to $299 on the wrong problem.

Libida vs bremelanotide nasal spray: how do they compare?

Libida discloses more about the tablet itself; several nasal sellers disclose less, although Hone is a notable exception. The bigger split is commercial: Libida publishes tablet counts and recurring charges, while nasal offers range from a $175 Wisp entry price to prepaid AgeMD programs. None has product-specific comparative evidence.

The HRT Index Verification Standard — commercial details checked against public seller pages and policies on August 11, 2026. This is a public-disclosure comparison, not a quality score. The seven differences that decide the comparison are route and formula, public dose, package yield, evidence, price and renewal, route history, and life-stage and safety fit.

Evidence labels: Compounded-product details are seller-stated unless a calculation is identified; Vyleesi label facts are FDA-verified; “not public” means the detail was not found on the pages and policies reviewed, not that it does not exist.

Decision factor	Libida — Inner Balance	Bremelanotide nasal spray — current sellers	Vyleesi — FDA-approved benchmark
Finished product	Compounded sublingual tablet	Compounded nasal solution; formula varies by seller	FDA-approved single-dose subcutaneous autoinjector
Disclosed drug components	Bremelanotide plus oxytocin	Bremelanotide is disclosed; exact inactive formula usually is not	Bremelanotide
Public strength	1 mg bremelanotide + 20 IU oxytocin per tablet	Wisp, AgeMD and beyondMD: not published on the public product page. Hone: 1 mg per spray	1.75 mg/0.3 mL per autoinjector
Public package yield	10, 20 or 30 tablets	Wisp, AgeMD and beyondMD: not published. Hone: 10 sprays per 28 days	Four autoinjectors in the current direct-delivery offer
FDA-approved finished product?	No	No	Yes
Product-specific trial	Not found	Not found for a current commercial spray	Two randomized Phase 3 trials in 1,247 premenopausal women
Head-to-head comparison	None found	None found	Not applicable
Seller timing claim	30–60 minutes before intimacy	Wisp: 45–60 minutes. Hone: 45–60 minutes	At least 45 minutes before anticipated sexual activity
Public maximum-use instruction	Product page: no more than one tablet in 72 hours. Separate Inner Balance articles state no more than about eight doses monthly. Follow the prescription label	Wisp: public page says one to two sprays but does not publish a monthly ceiling. Hone: maximum 2 mg per use, once per 24 hours, no more than three times weekly	One per 24 hours; more than eight doses monthly is not recommended
Current public price	$249 one-time/10; $199 monthly/10; $249 every two months/20; $299 every three months/30	Wisp: starts at $175, one-time or subscription. AgeMD: $672/3 months, $1,224/6 months, or $2,244/12 months paid upfront. beyondMD: starts at $384. Hone: public price not located	Current manufacturer route: most eligible commercially insured patients may pay $0; $99 for a four-dose box without coverage, subject to program terms
Can cost per unit be calculated publicly?	Yes: $24.90, $19.90, $12.45 or $9.97 per tablet, depending on plan	Hone: the public yield is countable, but price was not found. Other sellers do not disclose enough public package data to calculate a reliable cost per spray	$24.75 per autoinjector at the current $99 four-dose cash offer
Renewal and cancellation	Product page says cancel anytime; recurring plans list their billing cadence	Wisp subscription renews unless cancelled at least 48 hours before the next period. AgeMD says programs may renew until cancelled; cancellation stops future charges	Not a subscription requirement of the medication itself
Returns or refunds	Libida is expressly excluded from Inner Balance’s money-back guarantee	Wisp does not accept returns or exchanges. AgeMD says dispensed prescriptions are generally non-returnable and non-refundable once shipped, except specified errors	Pharmacy and savings-program terms apply
Pharmacy named on public product page?	No — “certified U.S. pharmacy”	Wisp: not named on product page. AgeMD: third-party “FDA-registered pharmacy,” not named. Hone: not named in the dosing article	BlinkRx is named for the current direct-delivery route
Public state information	Inner Balance states it serves all 50 states; product eligibility still depends on clinician approval	Wisp states it prescribes and ships in all 50 states. beyondMD says its providers serve all 50 states, subject to product availability. Hone excludes AL, AR, HI, KY, NC, PA, SC, SD and VT. AgeMD requires an active state but does not publish a product-specific list on the page reviewed	Prescription access and savings eligibility vary by patient, pharmacy and program rules
Routine labs included?	Not advertised on the public Libida page	Not advertised as an included product feature on the public pages reviewed	No routine lab package is part of the drug’s label

One row deserves a second look. Inner Balance publishes the strength, but puts it in a help-center article rather than the main product-and-pricing block. Most nasal sellers disclose even less. Hone publishes 1 mg per spray and ten sprays per 28 days, proving that a seller can put the information in public without making the page unreadable.

Source links: Inner Balance Libida product page · Inner Balance help-center formula · Inner Balance public pricing · Inner Balance refund policy · Wisp product · Wisp terms · AgeMD product · AgeMD terms · Hone dosing and availability · Vyleesi prescribing information · Vyleesi access offer

The right provider isn’t the same for every woman

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

What did The HRT Index actually verify?

We checked the finished-product disclosures, prices, billing terms, state limits, FDA labels, and cited trials rather than borrowing one seller’s description of another route. Where a public page does not disclose a strength, bottle yield, exact first charge, pharmacy, or refund path, the gap is labeled instead of filled with a guess.

Verified on August 10–11, 2026

Libida’s public strength: 1 mg bremelanotide plus 20 IU oxytocin per tablet, published in an Inner Balance help-center article dated March 26, 2026.
Inner Balance’s four public Libida purchase options, tablet counts, and billing cadence.
Inner Balance’s contradiction on HSA/FSA eligibility: the Libida product page says eligible, while the company’s dedicated HSA/FSA page says only Oestra is currently eligible.
Inner Balance’s refund policy expressly excludes Libida from its money-back guarantee, even though recurring plans can be cancelled to stop future renewals.
Wisp’s $175 entry price, one-time-or-subscription choice, 48-hour subscription cancellation deadline, no-returns policy, and 50-state platform claim.
AgeMD’s actual prepaid commitments: $672, $1,224 or $2,244, rather than only the effective monthly figures shown in larger type.
Hone’s public 1 mg-per-spray strength, ten-spray default supply, dosing ceiling, storage instruction, and nine excluded states.
The current Vyleesi prescribing information and the manufacturer’s current $99 four-dose cash route.
The December 2025 Addyi label revision and current manufacturer price.
Palatin’s historical statement explaining why it discontinued nasal bremelanotide as a first-line route for sexual dysfunction, plus Palatin’s 2023 sale of Vyleesi to Cosette Pharmaceuticals.
FDA’s current explanation of what compounded status does — and does not — mean.

Still not publicly resolved

The pharmacokinetics and systemic exposure of the exact Libida tablet sold today.
Product-specific pharmacokinetics for the current commercial nasal sprays.
Wisp’s public concentration, milligrams per spray, bottle volume, and dose yield.
AgeMD’s public strength, bottle yield, product-specific state list, and exact pharmacy identity.
beyondMD’s public strength, package yield, detailed renewal terms, and pharmacy identity.
Hone’s public price for the spray.
A product-specific randomized trial for Libida or any current commercial nasal spray.
A head-to-head trial comparing the two routes.

Every competing product page publishes the first kind of list. Very few publish the second.

Are Libida and bremelanotide nasal spray the same thing?

No. Both contain bremelanotide, but that does not make the finished products equivalent. Libida is a compounded sublingual tablet with added oxytocin. Nasal products are compounded liquids with seller-specific concentrations and directions. Route, formula, dose delivery, absorption, package yield, and prescribing instructions all differ.

This is the single biggest source of confusion in the category, so let’s be precise.

An ingredient name tells you which drug is present. It does not tell you how much reaches the bloodstream from a tablet, spray, or injection. The FDA approves finished products with a specific formulation, route, dose, manufacturing process, evidence package, and label. Approval does not transfer to every product that contains that drug.

A sublingual tablet must dissolve and remain in contact with oral tissue; some material may be swallowed. A nasal liquid must reach nasal tissue, remain there long enough to be absorbed, and contend with device performance, spray technique, mucus, mucociliary clearance, rhinitis, and congestion. An injection places a measured amount under the skin.

Those are not cosmetic differences. They are why comparing “1 mg” in one route with “1 mg” in another can create false precision.

Where does oxytocin fit?

Libida contains oxytocin; the nasal products reviewed here disclose bremelanotide without oxytocin. That is a genuine formula difference and a major part of Inner Balance’s positioning.

A formula difference is not automatically a clinical advantage. The randomized oxytocin research in women does not establish that adding oxytocin improves the effect of a compounded bremelanotide tablet. We break down the actual trial below.

What should a transparent seller say?

A transparent page should tell you four things without making you hunt:

This exact finished product is compounded and is not FDA-approved.
The prescribed strength and dose will appear on your prescription label.
Evidence from Vyleesi or an older intranasal study does not prove the current tablet or spray works the same way.
The total charge, quantity, renewal date, cancellation process, pharmacy identity, and state limits are visible before payment.

That standard is not anti-compounding. It is the minimum information a cash-pay prescription buyer needs.

Is Libida or bremelanotide nasal spray FDA-approved?

No. Neither Libida nor a compounded bremelanotide nasal spray is FDA-approved. The FDA-approved bremelanotide product is Vyleesi, a 1.75 mg/0.3 mL subcutaneous autoinjector indicated for premenopausal women with acquired, generalized HSDD that causes marked distress and is not explained by another condition, relationship problem, medication, or drug.

FDA’s wording is direct: compounded drugs are not FDA-approved, so FDA does not verify their safety, effectiveness, or quality before they are marketed. FDA also says compounded drugs should be used when a patient’s medical need cannot be met by an FDA-approved drug.

That does not mean every compounded prescription is unlawful or inappropriate. Compounding can meet legitimate patient needs when the prescription and compounder satisfy the applicable federal and state requirements. It does mean the finished tablet or spray has not gone through the FDA approval process that produced Vyleesi’s dose, label, contraindications, manufacturing controls, and product-specific evidence.

Why “off-label” can blur the distinction

Off-label prescribing normally means a clinician prescribes an FDA-approved finished product outside its approved indication, population, dose, or route. The approved product still has an FDA-reviewed label.

A compounded finished product is unapproved. Calling a compounded tablet or spray merely “off-label” can leave a reader thinking FDA reviewed that finished product but not this use. It did not.

The clean sentence is: Libida and current commercial bremelanotide nasal sprays are compounded prescription products that are not FDA-approved.

Not sure whether an FDA-approved or compounded route fits your situation?
That answer changes with your age, symptoms, history, medication preferences, insurance, and state. Use Find My HRT Path to identify the questions and provider model that fit your situation → The tool does not diagnose or prescribe, and it flags when online care may not be the right starting point.

Why did Palatin stop developing nasal bremelanotide for sexual dysfunction?

Palatin reported that blood-pressure increases in some patients, combined with significant variation in plasma levels, led it to discontinue nasally administered bremelanotide as a first-line therapy for sexual dysfunction. It shifted development to subcutaneous administration to reduce exposure variability. That is a route-history fact, not a verdict on every spray compounded today.

This is the fact we promised you at the top.

Palatin developed bremelanotide and studied nasal formulations in erectile dysfunction and female sexual dysfunction, including studies in premenopausal and postmenopausal women. In its historical statement, the company said two issues drove the route change:

Blood-pressure increases observed in some patients receiving nasal bremelanotide.
Significant variation in plasma levels.

Palatin then reported that subcutaneous administration substantially reduced variability in plasma exposure. The FDA-approved product that eventually reached the market is an injection.

One ownership correction matters: Palatin no longer owns Vyleesi. It completed the sale of Vyleesi to Cosette Pharmaceuticals in December 2023.

Read the damaging admission correctly

The old nasal program does not establish that Wisp’s, AgeMD’s, beyondMD’s, or Hone’s current compounded spray is unsafe. Those products can differ in concentration, excipients, device, dose, and preparation.

But the opposite claim is also unavailable. The sellers do not publish product-specific pharmacokinetic studies showing that their current spray solved the exposure variability Palatin reported.

So here is the honest version:

One of the two routes you are comparing has a documented history in which the molecule’s developer saw enough blood-pressure and exposure variability to move away from nasal delivery for this use. That deserves weight in your decision. It does not create a head-to-head winner by itself.

No CTA here. We are not going to monetize a regulatory and safety-history section.

Primary sources: Palatin’s route-history statement · Palatin’s sale of Vyleesi to Cosette

Does sublingual or nasal bremelanotide work better?

Nobody can answer that from current evidence. No randomized trial compares Libida with a commercial nasal spray, and no product-specific trial establishes the efficacy of either finished compounded product. The route changes the absorption problem; it does not create a defensible efficacy winner without measured exposure and comparative outcomes.

The evidence ladder

Evidence tier	What exists	What it can support
FDA-reviewed evidence	Vyleesi 1.75 mg subcutaneous injection in 1,247 premenopausal women with acquired, generalized HSDD	Efficacy and safety conclusions for that approved injection and labeled population
Older human intranasal research	Early intranasal bremelanotide studies, including a controlled study in premenopausal women with sexual arousal disorder	Biological activity and historical route evidence — not proof for a current seller’s spray
Adjacent oxytocin research	Intranasal oxytocin trials in women	Evidence about oxytocin at a different route, dose and product — not Libida
Seller instructions	Timing, dose directions, duration claims and program rules	What the seller tells patients; not comparative proof
Missing	Libida finished-product trial, current commercial nasal-spray trial, head-to-head route trial	No evidence-based efficacy winner

What can change nasal delivery?

Peer-reviewed nasal-delivery reviews identify several variables that can affect deposition and absorption:

Formulation concentration, viscosity and pH.
Device design, spray plume and delivered volume.
Spray angle and technique.
Mucus and mucociliary clearance.
Rhinitis, congestion, inflammation and other changes in nasal condition.
The limited volume the nasal cavity can comfortably retain.

Sublingual delivery has its own variables: dissolution, contact time, saliva, swallowing, formulation, and the molecule’s ability to cross oral tissue.

Neither route gets a free pass. The point is not that nasal must be worse. The point is that neither seller group publishes product-specific systemic-exposure data that lets you compare them honestly.

Why we will not compare milligrams across routes

Libida’s public tablet contains 1 mg bremelanotide. Hone says its spray delivers 1 mg per spray. Vyleesi injects 1.75 mg.

Those numbers look easy to rank. They are not.

A milligram under the tongue, a milligram deposited in the nose, and a milligram injected under the skin do not establish equal systemic exposure. Without pharmacokinetic data for each finished formulation, the number cannot tell you which route is stronger, faster, safer, or more reliable.

That is why the most useful comparison is not “which has the bigger milligram number?” It is which seller tells you exactly what is prescribed, how the dose is delivered, how many doses you receive, how often you may use it, what data supports that finished product, and what your card will be charged.

The disclosure test

Product or seller	Strength public?	Yield public?	Product-specific pharmacokinetics public?	Full commitment visible before intake?
Libida	Yes	Yes	No	Yes on a separate pricing article
Wisp nasal solution	No	No	No	Entry price and one-time/subscription choice; exact package commitment not public
AgeMD nasal spray	No	No	No	Yes — three prepaid program totals can be calculated from the page
beyondMD nasal spray	No	No	No	Starting price only
Hone nasal spray	Yes	Yes	No	Public product price not found

Hone proves the problem is not that nasal-spray disclosures are impossible. Most sellers have simply chosen not to publish them.

Ask this before you pay

“What exact strength will appear on my prescription label, how many milligrams are in each dose, how many doses will I receive, and do you have pharmacokinetic or clinical data for this finished formulation?”

For a spray, add:

“What is the concentration, how many milligrams does each spray deliver, how many sprays are in the bottle, what is the maximum frequency, and what amount will be charged today and at renewal?”

A prescriber who answers plainly has told you something good. A company that cannot show the charge and quantity before payment has told you something too.

Does the oxytocin in Libida add a proven advantage?

No published trial establishes that Libida’s added oxytocin makes it work better than bremelanotide alone. A small randomized, double-blind, placebo-controlled crossover trial of intranasal oxytocin in 30 premenopausal and postmenopausal women found improvements in both periods but no significant treatment effect over placebo.

The marketing story is intuitive: bremelanotide creates the spark; oxytocin creates closeness; women need both. It sounds complete. Then you look at what happened when oxytocin was tested.

In the 2015 trial by Muin and colleagues, women aged 41 to 65 used intranasal oxytocin or placebo before intercourse for eight weeks, crossed over after washout, and completed validated sexual-function and distress measures.

Measure	Oxytocin period	Placebo period
Sexual function score	+26%	+31%
Sexual quality of life	+144%	+125%
Sexual interest and desire	+29%	+23%
Sexual distress — lower is better	−36%	−45%

The investigators reported no significant treatment effect, sequence effect, or interaction.

Being fair about the study: it included only 30 women, used intranasal oxytocin rather than sublingual oxytocin, and tested oxytocin by itself rather than beside bremelanotide in a tablet. It cannot prove Libida does not work.

It does set the right expectation. Oxytocin is a real ingredient difference, but “bonding pathway” is not a demonstrated product advantage until the finished combination is tested. Another controlled study found no change in several standard measures of sexual drive and arousal, although some subjective orgasm and contentment outcomes differed.

So is oxytocin a reason to choose Libida?

It can be a preference if you understand the evidence. It is not a proven reason to expect a better result.

Studies: Muin et al., 2015 · Behnia et al., 2014

How much do Libida and bremelanotide nasal spray cost?

Libida costs $249 one-time for ten tablets or $199, $249, or $299 on recurring plans; its lowest unit price is $9.97 per tablet. Wisp starts at $175. AgeMD requires $672 to $2,244 upfront. beyondMD starts at $384. Do not confuse an effective monthly figure with today’s charge or a tablet price with a guaranteed successful experience.

What will your card actually be charged?

Seller and plan	Headline or effective rate	Quantity publicly disclosed	Charge shown by seller	Renewal
Inner Balance one-time	—	10 tablets	$249 once	None stated
Inner Balance monthly	$199/month	10 tablets	$199 monthly	Monthly until cancelled
Inner Balance two-month	$124.50 effective monthly	20 tablets	$249 every two months	Every two months until cancelled
Inner Balance three-month	“From $99.70/month”	30 tablets	$299 every three months	Every three months until cancelled
Wisp	Starts at $175	Not public	Confirm at checkout	One-time or subscription available
AgeMD three-month	$224/month effective	Not public	$672 upfront	Program may renew until cancelled
AgeMD six-month	$204/month effective	Not public	$1,224 upfront	Program may renew until cancelled
AgeMD 12-month	$187/month effective	Not public	$2,244 upfront	Program may renew until cancelled
beyondMD	Starts at $384	Not public	Confirm at checkout	Not publicly resolved
Hone	Not located publicly	10 sprays/28 days	Confirm during intake	Membership/program terms apply

The $99.70 Inner Balance headline is the $299 three-month charge divided by three and rounded. The exact arithmetic is $99.67 per month. The three-month plan is still the lowest published unit price; the number beside the checkout button simply needs to be understood as $299 charged at once, not $99.70 charged monthly.

Libida unit-cost math

Libida option	Charge	Tablets	Acquisition cost per tablet
One-time	$249	10	$24.90
Monthly subscription	$199	10	$19.90
Two-month subscription	$249	20	$12.45
Three-month subscription	$299	30	$9.97

That last figure is a tablet acquisition cost, not proof of “$9.97 per successful experience.” One tablet may be one planned use, but the seller has not published a controlled product trial establishing the probability, magnitude, or duration of benefit from each tablet.

The subscription-stockpile problem

In Vyleesi’s Phase 3 program, most participants used the injection two or three times a month and no more than once a week. That frequency does not tell us how often a Libida customer will use Libida, but it is a reasonable scenario to test because these are on-demand products.

At two uses per month, 30 tablets could last 15 months. At three uses per month, they could last ten months.

If the three-month subscription continues to renew four times in a year, the customer pays $1,196 and receives 120 tablets. A person using 24 tablets that year would have paid about $49.83 in cash outflow per dose actually used that year and accumulated 96 tablets. A person using 36 would have paid about $33.22 per dose actually used that year and accumulated 84.

That is not an inevitable cost. Inner Balance says you can cancel anytime. It is the reason to calendar your renewal date rather than treating a low unit price as automatically low annual spending.

There is another large pricing gap: twelve monthly renewals cost $2,388 for 120 tablets, while four three-month renewals cost $1,196 for the same published quantity. That is a $1,192 annual difference for identical tablet count if both subscriptions run for a year.

Can nasal cost per dose be calculated?

Not for most sellers from public data.

Wisp publishes the $175 starting price but not concentration, bottle volume, milligrams per spray, or bottle yield.
AgeMD publishes the prepaid program totals but not the public strength or yield.
beyondMD publishes a starting price but not the public strength or yield.
Hone publishes 1 mg per spray and ten sprays per 28 days, but we did not locate a public product price.

The information exists somewhere in the prescribing and dispensing process. The problem is that the buyer cannot compare it before entering that process.

Is Libida HSA/FSA eligible?

Inner Balance’s public pages contradict each other.

The Libida product page displays “HSA/FSA Eligible.”
Inner Balance’s dedicated HSA/FSA page says: “Currently, only OESTRA is eligible for HSA/FSA payments.”

Do not build your affordability decision on the product-page badge. Ask Inner Balance and your plan administrator for written confirmation for the exact Libida charge before using an HSA or FSA card.

Before you pay, write down five numbers
Charged today.
Quantity dispensed.
Milligrams per prescribed dose.
Next renewal date and amount.
Cancellation deadline.
Then use Find My HRT Path if the real question is whether this product category fits your symptoms, age, risk history, insurance and state — not merely which checkout is cheaper.

What are the side effects, and who should not take either one?

The best quantified safety evidence belongs to Vyleesi injection, not to either compounded route. In the approved product’s trials, nausea occurred in 40% of participants versus 1.3% with placebo, and 18% stopped because of adverse reactions versus 2% on placebo. Bremelanotide also transiently raises blood pressure.

What the FDA-approved label reports

Finding with Vyleesi injection	Result
Nausea	40.0% vs 1.3% placebo
Flushing	20.3% vs 0.3% placebo
Headache	11.3% vs 1.9% placebo
Vomiting	4.8% vs 0.2% placebo
Discontinued because of adverse reactions	18% vs 2% placebo
Focal hyperpigmentation with labeled-frequency use	1%
Focal hyperpigmentation after daily dosing for eight days in a separate study	38%
Maximum mean blood-pressure change	About +6 mmHg systolic and +3 mmHg diastolic, peaking two to four hours after dosing

These are injection data. They should not be copied onto a compounded tablet or spray as though route and exposure do not matter. They are the clearest human evidence about bremelanotide’s known risks and the safety questions a prescriber should address.

The heart-history wording matters

Vyleesi is contraindicated in people with:

Uncontrolled hypertension.
Known cardiovascular disease.

The label also says blood pressure should be well controlled and cardiovascular risk considered before treatment and periodically afterward.

Inner Balance’s public Libida page uses the narrower phrase “untreated heart disease” in its self-screening copy. Treated cardiovascular disease is still known cardiovascular disease. A product quiz should not override the approved label’s safety benchmark or a clinician who has your records.

The pigmentation detail matters too

The Vyleesi label reports focal hyperpigmentation in about 1% of patients using up to eight doses a month and says resolution was not confirmed in all patients. More frequent dosing increases risk.

That is different from implying pigmentation happens only after someone exceeds instructions. The 1% label finding occurred within the labeled monthly frequency.

One interaction almost nobody mentions

Bremelanotide slows gastric emptying and can reduce exposure to some oral medications. The Vyleesi label specifically says to avoid orally administered naltrexone used for alcohol or opioid addiction because treatment failure can have severe consequences.

If you take oral medication whose timing or threshold concentration matters — including some antibiotics or rapid-onset pain medicines — put it on the prescriber’s review list.

Who should not start from a product page

Anyone with uncontrolled high blood pressure or known cardiovascular disease.
Anyone pregnant, trying to conceive, or breastfeeding without direct clinician guidance.
Anyone taking oral naltrexone for alcohol or opioid-use disorder.
Anyone whose low desire began with a new medication or untreated medical or psychiatric condition.
Anyone for whom sex hurts. Pain, dryness and genitourinary syndrome of menopause need their own assessment and may have more direct treatments.
Anyone who needs the exact product’s FDA-reviewed safety profile before taking it.

No CTA here. This section exists to protect you.

Source: Vyleesi full prescribing information

Does either product have FDA-approved evidence for postmenopausal women?

No. Vyleesi’s label says it is not indicated for postmenopausal women, so neither Libida nor a nasal spray can borrow an approved postmenopausal bremelanotide claim from it. Since December 2025, Addyi is FDA-approved for women under 65 with acquired, generalized HSDD regardless of menopausal status — with meaningful trade-offs.

If you are postmenopausal, this may change your plan more than the tablet-versus-spray question.

What does the bremelanotide label say?

Vyleesi is indicated for premenopausal women with acquired, generalized HSDD. Its label explicitly says it is not indicated for postmenopausal women or men.

Older intranasal bremelanotide research included women, and Palatin reported studying the route in premenopausal and postmenopausal populations. That history is not an FDA-approved postmenopausal indication, and it is not a trial of today’s commercial sprays.

A seller may prescribe a compounded product after an individual evaluation. The seller cannot turn that decision into FDA-approved postmenopausal evidence.

What changed with Addyi in December 2025?

Addyi’s revised label covers women under 65 with acquired, generalized HSDD that causes marked distress or interpersonal difficulty and is not due to another medical or psychiatric condition, relationship problem, medication, or drug.

The postmenopausal evidence came from a 24-week randomized, double-blind, placebo-controlled trial in which 447 women received Addyi and 455 received placebo. The average age was 55.

Addyi is a real approved option with real trade-offs:

100 mg every night at bedtime, not on demand.
A boxed warning for hypotension and syncope in certain settings.
Wait at least two hours after one or two alcoholic drinks before the bedtime dose; skip the dose after three or more drinks that evening.
Contraindicated with moderate or strong CYP3A4 inhibitors and in hepatic impairment.
Stop after eight weeks if symptoms have not improved.
Not indicated at age 65 or older.

Current manufacturer pricing says eligible insured patients may pay as little as $20 per month, while the cash price through PhilRx is $149 per month. Confirm your own coverage and eligibility; neither figure is universal.

Where does testosterone fit?

Low-dose transdermal testosterone is an evidence-based off-label option for carefully selected postmenopausal women with HSDD after other contributing causes have been addressed. It is not a universal answer and it does not erase the need for diagnosis, dose control, monitoring, and long-term safety discussion.

Two caveats travel with every responsible testosterone recommendation:

There is no FDA-approved systemic testosterone product for women in the United States. Clinicians who use it for HSDD prescribe off-label and aim to keep levels in the physiologic premenopausal female range.
Testosterone is a Schedule III controlled substance in the United States. It requires a prescription from a licensed prescriber. Expert guidance does not treat pellets, injections that produce supraphysiologic levels, or compounded products as interchangeable with the studied low-dose transdermal approach.

The honest postmenopause summary

The FDA-approved bremelanotide product is not indicated for postmenopausal women. Addyi is now approved for women under 65 who meet its HSDD criteria, but it is daily and carries alcohol, drug-interaction and hypotension rules. Testosterone can be considered off-label in selected women, but no female systemic product is FDA-approved in the United States and it is a controlled prescription drug.

None of those is a decision to make from a product page — including ours.

Postmenopausal and unsure which fork applies?
Use Find My HRT Path before choosing a seller → It helps organize the questions that change the starting point — painful sex versus low desire, local versus systemic treatment, approved versus compounded medication, cardiovascular history, insurance, and whether online care is appropriate.

Sources: Addyi prescribing information · Addyi current access pricing · ISSWSH testosterone guideline · DEA drug scheduling

What about cheap “research use only” bremelanotide vials?

Do not treat a “research use only” peptide vial as a cheaper version of either prescription product. Its label is not proof of identity, strength, sterility, purity or dose. It also removes the prescriber, dispensing pharmacy, patient-specific instructions and accountability that exist in the telehealth products compared here.

You will find these vials while searching because the price can be dramatically lower. We are not linking to them.

The identity and quality problem

A powder or liquid in a vial cannot be authenticated by appearance. Confirming peptide identity and purity requires analytical testing. A website certificate is not the same as a patient-specific pharmacy dispensing record, and “for research use only” does not turn self-administration into clinical care.

FDA separately lists Melanotan II — a related melanocortin peptide sold online — among bulk substances that may present significant safety risks, citing peptide-related impurities and published serious adverse-event reports that include melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.

The responsible conclusion is not a kitchen-counter molecular-weight challenge. It is simpler: do not self-administer an unverified research vial and assume the name on the label proves what is inside.

Registration is not approval

Sellers sometimes describe a medication as coming from an “FDA-registered pharmacy.” Registration does not mean FDA approved the pharmacy’s compounded product.

FDA explains that state boards of pharmacy generally have primary day-to-day oversight of state-licensed pharmacies that are not registered as outsourcing facilities. FDA primarily oversees and inspects registered 503B outsourcing facilities on a risk-based schedule. The category matters; the exact compounder still needs to be identified.

Both Libida and the commercial nasal products at least use a prescription-and-pharmacy pathway. That is a real advantage over a research vial. You should still ask which pharmacy will dispense your medication and what will appear on the prescription label.

No CTA here either.

Sources: FDA compounding questions and answers · FDA substances that may present significant safety risks

So which one should you choose?

There is no proven efficacy winner. Choose only after the prescriber puts the exact dose, route, package yield, safety screening, total charge and renewal terms in writing. Libida wins on public tablet strength and countability. A nasal spray wins if avoiding oxytocin and using a spray are your priorities. Neither wins on product-specific evidence.

Who wins each decision category?

Category	Winner	Why
FDA-reviewed evidence	Neither — Vyleesi	The randomized evidence and label attach to the approved injection
Public strength disclosure	Libida over most nasal sellers	Inner Balance publishes 1 mg bremelanotide + 20 IU oxytocin; Wisp, AgeMD and beyondMD do not publish strength
Best nasal disclosure	Hone	Publishes 1 mg per spray, ten sprays per 28 days, dose ceiling, storage and state exclusions
Countable package before purchase	Libida	Tablet quantities are public
Avoiding nasal delivery variables	Libida	It does not rely on nasal deposition or nasal condition
Avoiding added oxytocin	Nasal spray	The reviewed nasal products disclose bremelanotide without oxytocin
Avoiding the historically discontinued route	Libida	Palatin moved away from nasal delivery for this use after BP and plasma-level variability findings
Lowest verified Libida unit price	Three-month plan	$299/30 = $9.97 per tablet, but the card is charged $299 and the plan renews
Lowest current approved-product cash offer	Vyleesi through the manufacturer route	$99 for four doses without coverage, subject to program terms
Buying without a recurring plan	Libida or Wisp	Libida lists a $249 one-time option; Wisp says one-time or subscription
Clear public cancellation deadline	Wisp	At least 48 hours before the next refill or renewal period
Product-specific efficacy evidence	No winner	No finished-product trial was found for Libida or a current commercial spray

The damaging admission

Here is what we cannot do for you, and neither can the sellers: tell you how much bremelanotide from Libida or most current sprays will reliably reach your bloodstream.

Inner Balance publishes the tablet’s ingredients and strength but no product-specific pharmacokinetic study. Hone publishes the spray strength and yield but no product-specific pharmacokinetic study. Most other nasal sellers do not even publish the dose and yield needed for a basic public comparison.

If a measured, FDA-reviewed dose and finished-product evidence are non-negotiable, neither compounded option is your product. That is exactly what approval buys: a defined formulation, dose, label, manufacturing controls, contraindications and evidence attached to the finished product.

But be clear about what the trade costs you in lived experience. Vyleesi requires an injection before anticipated sexual activity. Addyi is a nightly pill, not an on-demand product, and carries alcohol and interaction rules. A woman can understand those advantages and limitations and still value a needle-free, on-demand route.

Wanting that does not make you careless. It means convenience matters. The responsible version of that preference is not blind trust — it is getting the prescribed strength, charge, renewal, pharmacy and safety plan in writing before you pay.

What would change our verdict?

We would update this page if any of the following appeared:

A published trial of Libida as the finished tablet sold to patients.
A published trial of a current commercial bremelanotide nasal spray.
A head-to-head comparison of sublingual and nasal finished products.
Public pharmacokinetic data for either product.
Wisp, AgeMD and beyondMD publishing concentration, dose per spray and bottle yield.
Inner Balance moving the tablet strength and dosing ceiling into the main product-and-pricing block.
A needle-free bremelanotide product receiving FDA approval.

Until one of those happens, anyone declaring which compounded product works better is guessing.

The next useful step is not another sales page
Take the dose-and-billing questions above to a licensed prescriber who can review the cause of low desire, your blood pressure and cardiovascular history, every oral medication you take, pregnancy status, and whether painful sex or menopause symptoms need a different first treatment. Find the provider model that fits those constraints →

Are there trustworthy customer reviews of either product?

Independent, product-specific reviews are hard to verify for both Libida and current bremelanotide nasal sprays. Most visible testimonials are seller-hosted, company-wide ratings, affiliate content, press releases, or discussions that do not identify the prescribed strength. That is not enough to compare efficacy.

We deliberately excluded:

Seller-hosted testimonials making medical-outcome claims.
Company-wide Trustpilot scores presented near one specific product.
Press-release review totals that could not be matched to a transparent review pool.
Reddit posts as evidence of safety, efficacy, FDA status or typical results.
Reviews of an unidentified “PT-141 spray” that omit concentration, dose, pharmacy and date.

A customer can tell you whether billing was confusing, shipping was late, support responded, cancellation worked, or a package arrived damaged. A customer review cannot establish the product’s FDA status, systemic exposure, average efficacy or comparative safety.

What makes a prescription-product review useful?

It names the exact product and strength. “PT-141 spray” without concentration is an unknown formulation.
It names the seller, dispensing pharmacy, plan and date. Prices and policies change.
It separates service from medicine. Billing and shipping are experience claims; efficacy requires controlled evidence.
It discloses where the review is hosted and whether an incentive existed.
It does not turn one person’s outcome into a medical promise.

The lack of a clean independent review pool is not proof that either product fails. It is a reason not to let testimonials settle a pharmacology question they cannot answer.

Frequently asked questions

Is bremelanotide nasal spray FDA-approved?

No. No bremelanotide nasal spray is FDA-approved. The FDA-approved bremelanotide product is Vyleesi, a 1.75 mg/0.3 mL subcutaneous autoinjector indicated for premenopausal women with acquired, generalized HSDD. Commercial sprays sold online are compounded products.

Is Libida FDA-approved?

No. Libida is a compounded sublingual prescription tablet. Inner Balance’s own product page states that it is compounded on an individual basis and that its claims have not been evaluated by FDA.

How much bremelanotide is in Libida?

Inner Balance’s help-center article dated March 26, 2026 lists 1 mg bremelanotide plus 20 IU oxytocin per tablet. That strength was not displayed in the main pricing block when this page was verified.

How much bremelanotide is in a nasal spray?

It depends on the seller and prescription. Hone publishes 1 mg per spray and a ten-spray default 28-day supply. Wisp, AgeMD and beyondMD did not publish strength and bottle yield on the public pages reviewed. Get the concentration, milligrams per spray and total spray count in writing.

Which one works faster?

No head-to-head timing study exists. Inner Balance says Libida is taken 30–60 minutes before intimacy; Wisp says 45–60 minutes; Hone says 45–60 minutes. Those are seller instructions, not a measured comparison proving one route starts faster.

How often can you take Libida?

Inner Balance’s product page says not to take more than one tablet in 72 hours. Separate Inner Balance articles state a maximum of about eight doses monthly. Follow the prescription label and ask the prescriber to resolve any difference between public pages before use.

How often can you use bremelanotide nasal spray?

The answer depends on the prescribed spray. Hone publishes a maximum of two 1 mg sprays per use, no more than once in 24 hours and no more than three times weekly. Wisp’s public page says one to two sprays but did not publish a monthly maximum. Do not import one seller’s directions into another seller’s bottle.

Can bremelanotide be used after menopause?

Vyleesi is not indicated for postmenopausal women. A clinician may make an individualized decision about a compounded product, but that is not an FDA-approved postmenopausal use. Addyi is now FDA-approved for women under 65 with acquired, generalized HSDD regardless of menopausal status.

Does insurance cover Libida or a nasal spray?

The reviewed compounded programs are marketed primarily as cash-pay products, and coverage cannot be assumed. Vyleesi and Addyi may be covered depending on the plan and eligibility. Confirm the exact prescription and benefit before relying on insurance reimbursement.

Is Libida HSA/FSA eligible?

Inner Balance’s pages conflict. The product page says yes; its dedicated HSA/FSA page says only Oestra is currently eligible. Get written confirmation from Inner Balance and your plan administrator before paying with pre-tax funds.

Can men use bremelanotide nasal spray?

Some nasal sellers market compounded bremelanotide to men. Vyleesi’s FDA-approved label says it is not indicated for men. That distinction must remain visible; seller prescribing is not an approved male indication.

How long do the effects last?

The Vyleesi label says duration of efficacy after each dose is unknown and the optimal administration window has not been fully characterized. Inner Balance advertises Libida effects lasting up to 72 hours; that is a seller claim for an unapproved finished product, not an FDA-reviewed duration finding.

Is it safe with blood-pressure medication?

A medication list alone cannot answer that. Bremelanotide transiently raises blood pressure, and Vyleesi is contraindicated in uncontrolled hypertension and known cardiovascular disease. A clinician should review your actual blood-pressure control, diagnosis, other cardiovascular risks and medications.

What if I have a cold or chronic nasal congestion?

Nasal condition, mucus and mucociliary clearance can affect nasal drug delivery. That does not prove a spray will fail, but it is a route-specific reason to ask how the prescriber handles rhinitis, congestion, nasal steroids and a missed or uncertain dose. Never repeat a spray because it “felt like it did not go in” unless your prescriber’s instructions explicitly say to.

Can I use either product with vaginal estrogen or menopausal hormone therapy?

Some sellers market their products for use alongside hormone therapy, but compatibility depends on your full regimen and health history. Bring every prescription, over-the-counter medication and supplement to the prescriber. Bremelanotide’s effect on gastric emptying can matter for orally administered drugs.

Are testosterone and bremelanotide interchangeable for low desire?

No. They are different prescription approaches with different evidence, dosing, monitoring and legal requirements. Testosterone for women is off-label in the United States, and testosterone is a Schedule III controlled substance requiring a licensed prescriber.

The bottom line

Libida and bremelanotide nasal spray both contain bremelanotide, but almost everything that determines a real prescription decision is different: route, formula, public strength, package yield, dosing instructions, absorption variables, charge, renewal, state access and what evidence exists for the finished product.

Neither compounded product is FDA-approved. Neither has a published finished-product trial. No study compares them. That is why there is no honest efficacy winner.

What you can control is what you know before you pay:

The exact strength and prescribed dose.
The quantity you receive.
The pharmacy that compounds it.
The amount charged today and at renewal.
The cancellation deadline and refund rule.
The cardiovascular and medication review.
Whether low desire is actually the right problem to treat first.

If you are postmenopausal, read that section again before ordering. The FDA-approved bremelanotide product is not indicated for your life stage, while Addyi is now approved for women under 65 who meet its HSDD criteria.

Still not sure which HRT program is right for you? Use our free matching tool.

Find My HRT Path →

How we researched this page

The HRT Index Verification Standard is our documented process: we read every published price, separate FDA-approved from compounded, verify state availability and insurance, and re-check on a fixed schedule — top providers monthly, the full roster quarterly. We evaluate providers on five pillars, in this order: clinical legitimacy, care quality, medication fit, price transparency, access.

For this page, we reviewed the current Vyleesi and Addyi prescribing information; FDA’s compounding guidance and safety-risk list; Palatin’s historical route statement and 2023 asset-sale announcement; Inner Balance’s Libida product, help-center, pricing and HSA/FSA pages; public product and policy pages from Wisp, AgeMD, beyondMD and Hone; and the peer-reviewed bremelanotide, oxytocin, nasal-delivery and testosterone literature listed below.

What this page did not do: We did not purchase either product, complete a medical intake, inspect a dispensed label, test cancellation, or analyze medication in a laboratory. Publicly undisclosed checkout and prescription details remain labeled as undisclosed.

Affiliate disclosure: This article contains no paid placement and no direct affiliate call to Libida or a bremelanotide nasal spray. Seller links in the sources are editorial evidence links. The HRT Index may earn commissions from separately disclosed provider relationships elsewhere on the site; compensation does not change this page’s verification standard or verdict.

This page is editorial research. It is not medically reviewed by a clinician and it is not medical advice. Talk to a licensed prescriber before starting, stopping or changing a prescription medication.

Sources

Regulatory and primary

Peer-reviewed and professional guidance

Commercial facts verified August 10–11, 2026

Keep comparing the evidence and route

Read the Libida review, compare Libida with Addyi, compare Libida with Vyleesi, or use the free Find My HRT Path tool.

Keep reading: